- Home
- BCLI vs INDP Comparison
BCLI vs INDP Comparison
Compare BCLI & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- INDP
- Stock Information
- Founded
- BCLI 2000
- INDP 2000
- Country
- BCLI United States
- INDP United States
- Employees
- BCLI N/A
- INDP N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- INDP Health Care
- Exchange
- BCLI Nasdaq
- INDP Nasdaq
- Market Cap
- BCLI 9.9M
- INDP 8.8M
- IPO Year
- BCLI N/A
- INDP N/A
- Fundamental
- Price
- BCLI $1.21
- INDP $0.50
- Analyst Decision
- BCLI Strong Buy
- INDP Strong Buy
- Analyst Count
- BCLI 1
- INDP 2
- Target Price
- BCLI $30.00
- INDP $8.50
- AVG Volume (30 Days)
- BCLI 35.3K
- INDP 1.2M
- Earning Date
- BCLI 03-31-2025
- INDP 03-13-2025
- Dividend Yield
- BCLI N/A
- INDP N/A
- EPS Growth
- BCLI N/A
- INDP N/A
- EPS
- BCLI N/A
- INDP N/A
- Revenue
- BCLI N/A
- INDP N/A
- Revenue This Year
- BCLI $170.09
- INDP N/A
- Revenue Next Year
- BCLI N/A
- INDP N/A
- P/E Ratio
- BCLI N/A
- INDP N/A
- Revenue Growth
- BCLI N/A
- INDP N/A
- 52 Week Low
- BCLI $1.05
- INDP $0.47
- 52 Week High
- BCLI $11.25
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- BCLI 30.68
- INDP 24.26
- Support Level
- BCLI $1.12
- INDP $0.58
- Resistance Level
- BCLI $1.59
- INDP $0.78
- Average True Range (ATR)
- BCLI 0.11
- INDP 0.14
- MACD
- BCLI -0.02
- INDP -0.03
- Stochastic Oscillator
- BCLI 17.31
- INDP 1.89
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.